Novel uses

Abstract

This invention relates to a new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of Interstitial lung diseases (ILDs), including IPF, and to combinations for such uses.

1 . A method of treating Interstitial lung diseases (ILDs), comprising administering to a human in need thereof a therapeutically effective amount of compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo [1,2-α]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or a pharmaceutically acceptable salt thereof. 
     
     
         2 . A method of treatment according to  claim 1 , wherein the Interstitial lung disease (ILD) is idiopathic pulmonary fibrosis (IPF). 
     
     
         3 . A method of treatment according to  claim 1 , comprising administering to a human in need thereof a therapeutically effective amount of 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or a pharmaceutically acceptable salt thereof in combination with a second drug substance which is selected from either pirfenidone or nintedanib. 
     
     
         4 . A method of treatment according to  claim 1 , wherein the pharmaceutically acceptable salt of the compound is maleate. 
     
     
         5 . A method of treatment according to  claim 1 , wherein the compound is orvepitant maleate Form  1 .